(IBDX) iShares Trust - iShares - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46436E3128

Corporate Bonds, Investment Grade

Description: IBDX iShares Trust - iShares

The iShares iBonds Dec2032 Term Corporate ETF (IBDX) is a target maturity ETF that provides investors with exposure to a diversified portfolio of corporate bonds maturing in December 2032. As a fixed income investment, its performance is closely tied to interest rates and credit spreads.

Key drivers of the ETFs performance include the overall direction of interest rates, with rising rates typically leading to declining bond prices, and the creditworthiness of the underlying corporate issuers. The ETFs holdings are likely comprised of investment-grade corporate bonds, making it sensitive to changes in credit spreads, which can be influenced by economic conditions and market sentiment.

To evaluate the ETFs potential performance, key metrics to monitor include its yield-to-maturity (YTM), duration, and credit quality. A higher YTM may indicate a more attractive income stream, but also potentially higher credit risk. Duration measures the ETFs sensitivity to interest rate changes, with longer durations indicating greater sensitivity. Credit quality is also crucial, as a higher proportion of lower-rated issuers can increase the risk of default.

The ETFs AUM of $1.189 billion indicates a moderate level of investor interest, which can contribute to liquidity. However, investors should be aware that the ETFs trading volume and liquidity can impact its ability to efficiently enter or exit positions.

Investors in IBDX should also consider the broader economic context, including the outlook for interest rates, inflation, and economic growth, as these factors can significantly impact the ETFs performance. A thorough analysis of these factors, combined with a detailed examination of the ETFs underlying holdings and key metrics, is essential for making informed investment decisions.

IBDX ETF Overview

Market Cap in USD 1,245m
Category Target Maturity
TER 0.10%
IPO / Inception 2022-06-28

IBDX ETF Ratings

Growth Rating 66.1%
Fundamental -
Dividend Rating 69.7%
Return 12m vs S&P 500 -11.7%
Analyst Rating -

IBDX Dividends

Dividend Yield 12m 4.96%
Yield on Cost 5y 5.73%
Annual Growth 5y 28.87%
Payout Consistency 100.0%
Payout Ratio %

IBDX Growth Ratios

Growth Correlation 3m 94.3%
Growth Correlation 12m 71.9%
Growth Correlation 5y 89.1%
CAGR 5y 6.86%
CAGR/Max DD 3y 0.85
CAGR/Mean DD 3y 4.00
Sharpe Ratio 12m 0.12
Alpha 0.00
Beta 0.974
Volatility 4.27%
Current Volume 371.1k
Average Volume 20d 189.6k
Stop Loss 24.9 (-3.2%)
Signal -0.73

What is the price of IBDX shares?

As of September 18, 2025, the stock is trading at USD 25.71 with a total of 371,073 shares traded.
Over the past week, the price has changed by +0.12%, over one month by +1.99%, over three months by +4.34% and over the past year by +4.70%.

Is iShares Trust - iShares a good stock to buy?

Yes. Based on ValueRay's Analyses, iShares Trust - iShares (NYSE ARCA:IBDX) is currently (September 2025) a good stock to buy. It has a ValueRay Growth Rating of 66.12 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IBDX is around 25.12 USD . This means that IBDX is currently overvalued and has a potential downside of -2.29%.

Is IBDX a buy, sell or hold?

iShares Trust - iShares has no consensus analysts rating.

What are the forecasts/targets for the IBDX price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 28.3 10%

Last update: 2025-09-08 04:41

IBDX Fundamental Data Overview

Market Cap USD = 1.24b (1.24b USD * 1.0 USD.USD)
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 1.25
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.24b USD (1.24b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 1.24b)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.24b / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(1.24b)/V(0.0) * Re(9.60%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)

Additional Sources for IBDX ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle